Amiprilose hydrochloride for the treatment of rheumatoid arthritis

David E. Trentham, Rose Fife, Beverly A. Carpenter, Jane Herron Box, Richard Trout, Marc E. Lanser

Research output: Contribution to journalArticle

Abstract

The intent of this study was to compare, in a monotherapy framework, an optimal dose of the synthetic hexose sugar, amiprilose hydrochloride (HCl), to a placebo in the treatment of rheumatoid arthritis. In this double-blind, randomized, multi-center study, patients first underwent a washout period from disease-modifying antirheumatic drugs. Those who subsequently met flare criteria within 14 days of discontinuing previously stable doses of nonsteroidal anti-inflammatory drugs were randomized to amiprilose HCl (103 patients) or a placebo (115 patients) for the subsequent 20 weeks. Glucocorticoid or nonsteroidal anti-inflammatory drugs use was not permitted. At the baseline, demographic and disease characteristics were similar in both groups. Of patients completing the course of therapy, 73% were in the amiprilose HCl group and 66% were in the placebo group. Using an intent-to- treat analysis, numeric trends favoring amiprilose HCl treatment were found for clinical and laboratory parameters of disease activity. Compared with the placebo group, statistically significant degrees of improvement were achieved for the number of swollen joints (p < 0.04), number of patients who experienced a ≥ 50% reduction in swollen joints (p < 0.04), number who improved by the Paulus composite score criteria (p < 0.02), improvement in the frequency distribution in Functional Class (p < 0.01), and improvement in the mean erythrocyte sedimentation rate (p < 0.03). Significant worsening in the duration of morning stiffness (p < 0.05) and in 4 of the 5 items in the clinical health assessment questionnaire (p < 0.004) occurred in the placebo but not in the amiprilose HCl group. No side effects clearly attributable to the drug were noted. This study provides an independent confirmation that the novel and nontoxic carbohydrate, amiprilose HCl, provides an effective approach to the treatment of rheumatoid arthritis. The Food and Drug Administration will now consider whether it should be approved for this indication.

Original languageEnglish
Pages (from-to)10-18
Number of pages9
JournalJournal of Clinical Rheumatology
Volume6
Issue number1
StatePublished - Feb 2000

Fingerprint

Rheumatoid Arthritis
Placebos
Anti-Inflammatory Agents
Therapeutics
Joints
Pharmaceutical Preparations
Antirheumatic Agents
Hexoses
Blood Sedimentation
United States Food and Drug Administration
Glucocorticoids
amiprilose
Carbohydrates
Demography
Health

Keywords

  • Carbohydrate drugs
  • Clinical trials
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Trentham, D. E., Fife, R., Carpenter, B. A., Box, J. H., Trout, R., & Lanser, M. E. (2000). Amiprilose hydrochloride for the treatment of rheumatoid arthritis. Journal of Clinical Rheumatology, 6(1), 10-18.

Amiprilose hydrochloride for the treatment of rheumatoid arthritis. / Trentham, David E.; Fife, Rose; Carpenter, Beverly A.; Box, Jane Herron; Trout, Richard; Lanser, Marc E.

In: Journal of Clinical Rheumatology, Vol. 6, No. 1, 02.2000, p. 10-18.

Research output: Contribution to journalArticle

Trentham, DE, Fife, R, Carpenter, BA, Box, JH, Trout, R & Lanser, ME 2000, 'Amiprilose hydrochloride for the treatment of rheumatoid arthritis', Journal of Clinical Rheumatology, vol. 6, no. 1, pp. 10-18.
Trentham DE, Fife R, Carpenter BA, Box JH, Trout R, Lanser ME. Amiprilose hydrochloride for the treatment of rheumatoid arthritis. Journal of Clinical Rheumatology. 2000 Feb;6(1):10-18.
Trentham, David E. ; Fife, Rose ; Carpenter, Beverly A. ; Box, Jane Herron ; Trout, Richard ; Lanser, Marc E. / Amiprilose hydrochloride for the treatment of rheumatoid arthritis. In: Journal of Clinical Rheumatology. 2000 ; Vol. 6, No. 1. pp. 10-18.
@article{9fb2774bc36546608d9f572e5ddc4f27,
title = "Amiprilose hydrochloride for the treatment of rheumatoid arthritis",
abstract = "The intent of this study was to compare, in a monotherapy framework, an optimal dose of the synthetic hexose sugar, amiprilose hydrochloride (HCl), to a placebo in the treatment of rheumatoid arthritis. In this double-blind, randomized, multi-center study, patients first underwent a washout period from disease-modifying antirheumatic drugs. Those who subsequently met flare criteria within 14 days of discontinuing previously stable doses of nonsteroidal anti-inflammatory drugs were randomized to amiprilose HCl (103 patients) or a placebo (115 patients) for the subsequent 20 weeks. Glucocorticoid or nonsteroidal anti-inflammatory drugs use was not permitted. At the baseline, demographic and disease characteristics were similar in both groups. Of patients completing the course of therapy, 73{\%} were in the amiprilose HCl group and 66{\%} were in the placebo group. Using an intent-to- treat analysis, numeric trends favoring amiprilose HCl treatment were found for clinical and laboratory parameters of disease activity. Compared with the placebo group, statistically significant degrees of improvement were achieved for the number of swollen joints (p < 0.04), number of patients who experienced a ≥ 50{\%} reduction in swollen joints (p < 0.04), number who improved by the Paulus composite score criteria (p < 0.02), improvement in the frequency distribution in Functional Class (p < 0.01), and improvement in the mean erythrocyte sedimentation rate (p < 0.03). Significant worsening in the duration of morning stiffness (p < 0.05) and in 4 of the 5 items in the clinical health assessment questionnaire (p < 0.004) occurred in the placebo but not in the amiprilose HCl group. No side effects clearly attributable to the drug were noted. This study provides an independent confirmation that the novel and nontoxic carbohydrate, amiprilose HCl, provides an effective approach to the treatment of rheumatoid arthritis. The Food and Drug Administration will now consider whether it should be approved for this indication.",
keywords = "Carbohydrate drugs, Clinical trials, Rheumatoid arthritis",
author = "Trentham, {David E.} and Rose Fife and Carpenter, {Beverly A.} and Box, {Jane Herron} and Richard Trout and Lanser, {Marc E.}",
year = "2000",
month = "2",
language = "English",
volume = "6",
pages = "10--18",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Amiprilose hydrochloride for the treatment of rheumatoid arthritis

AU - Trentham, David E.

AU - Fife, Rose

AU - Carpenter, Beverly A.

AU - Box, Jane Herron

AU - Trout, Richard

AU - Lanser, Marc E.

PY - 2000/2

Y1 - 2000/2

N2 - The intent of this study was to compare, in a monotherapy framework, an optimal dose of the synthetic hexose sugar, amiprilose hydrochloride (HCl), to a placebo in the treatment of rheumatoid arthritis. In this double-blind, randomized, multi-center study, patients first underwent a washout period from disease-modifying antirheumatic drugs. Those who subsequently met flare criteria within 14 days of discontinuing previously stable doses of nonsteroidal anti-inflammatory drugs were randomized to amiprilose HCl (103 patients) or a placebo (115 patients) for the subsequent 20 weeks. Glucocorticoid or nonsteroidal anti-inflammatory drugs use was not permitted. At the baseline, demographic and disease characteristics were similar in both groups. Of patients completing the course of therapy, 73% were in the amiprilose HCl group and 66% were in the placebo group. Using an intent-to- treat analysis, numeric trends favoring amiprilose HCl treatment were found for clinical and laboratory parameters of disease activity. Compared with the placebo group, statistically significant degrees of improvement were achieved for the number of swollen joints (p < 0.04), number of patients who experienced a ≥ 50% reduction in swollen joints (p < 0.04), number who improved by the Paulus composite score criteria (p < 0.02), improvement in the frequency distribution in Functional Class (p < 0.01), and improvement in the mean erythrocyte sedimentation rate (p < 0.03). Significant worsening in the duration of morning stiffness (p < 0.05) and in 4 of the 5 items in the clinical health assessment questionnaire (p < 0.004) occurred in the placebo but not in the amiprilose HCl group. No side effects clearly attributable to the drug were noted. This study provides an independent confirmation that the novel and nontoxic carbohydrate, amiprilose HCl, provides an effective approach to the treatment of rheumatoid arthritis. The Food and Drug Administration will now consider whether it should be approved for this indication.

AB - The intent of this study was to compare, in a monotherapy framework, an optimal dose of the synthetic hexose sugar, amiprilose hydrochloride (HCl), to a placebo in the treatment of rheumatoid arthritis. In this double-blind, randomized, multi-center study, patients first underwent a washout period from disease-modifying antirheumatic drugs. Those who subsequently met flare criteria within 14 days of discontinuing previously stable doses of nonsteroidal anti-inflammatory drugs were randomized to amiprilose HCl (103 patients) or a placebo (115 patients) for the subsequent 20 weeks. Glucocorticoid or nonsteroidal anti-inflammatory drugs use was not permitted. At the baseline, demographic and disease characteristics were similar in both groups. Of patients completing the course of therapy, 73% were in the amiprilose HCl group and 66% were in the placebo group. Using an intent-to- treat analysis, numeric trends favoring amiprilose HCl treatment were found for clinical and laboratory parameters of disease activity. Compared with the placebo group, statistically significant degrees of improvement were achieved for the number of swollen joints (p < 0.04), number of patients who experienced a ≥ 50% reduction in swollen joints (p < 0.04), number who improved by the Paulus composite score criteria (p < 0.02), improvement in the frequency distribution in Functional Class (p < 0.01), and improvement in the mean erythrocyte sedimentation rate (p < 0.03). Significant worsening in the duration of morning stiffness (p < 0.05) and in 4 of the 5 items in the clinical health assessment questionnaire (p < 0.004) occurred in the placebo but not in the amiprilose HCl group. No side effects clearly attributable to the drug were noted. This study provides an independent confirmation that the novel and nontoxic carbohydrate, amiprilose HCl, provides an effective approach to the treatment of rheumatoid arthritis. The Food and Drug Administration will now consider whether it should be approved for this indication.

KW - Carbohydrate drugs

KW - Clinical trials

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0034047580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034047580&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 10

EP - 18

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 1

ER -